Lineage Cell Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for LCTX, updated each market day.
LCTX AI Sentiment
AI sees no strong directional signal for Lineage Cell Therapeutics, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Sector
Exchange
Market Cap
$371,140,418
Cap Tier
Employees
77
Headquarters
CARLSBAD, CA
Listed Since
March 5, 1992
Website
LCTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
LCTX Volatility
Lineage Cell Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
